Retatrutide vs Tirzepatide: Triple Agonist vs Dual Agonist Comparison for Metabolic Research Retatrutide, a first-in-class triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors, demonstrates unprecedented weight loss efficacy in clinical trialsup to 24.2% body weight reduction at 48 weeks
Step 1: We will submit a new prior authorization for Zepbound (tirzepatide)
He also said the improvement appears tied to weight loss, so patients without obesity would not be expected to benefit in the same way
Difficult swallowing and breathing A sore throat with white patches A sore throat accompanied by a pink rash on the skin High fever Dark, red spots on the top of the mouth or tonsils A persistent sore throat that lasts for more than two days
We partner with you to manage your personalized titration schedule, monitor your progress, and help you maximize the health benefits of your treatment in a safe and supportive environment
Jastreboff AM et al